A problem when preparing the devices for use can delay diagnosis or treatment, leading BD to update its instructions for use.

The company will compete with a device Boston Scientific acquired for $850 million.

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

Many companies forecast specific tariff charges. Then the White House and China agreed to a 90-day pause in their trade ...

CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech ...

The Food and Drug Administration has authorized more medical devices that incorporate artificial intelligence. Keep track of ...